Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
作者信息
Robichaux Jacqulyne P, Elamin Yasir Y, Vijayan R S K, Nilsson Monique B, Hu Lemei, He Junqin, Zhang Fahao, Pisegna Marlese, Poteete Alissa, Sun Huiying, Li Shuai, Chen Ting, Han Han, Negrao Marcelo Vailati, Ahnert Jordi Rodon, Diao Lixia, Wang Jing, Le Xiuning, Meric-Bernstam Funda, Routbort Mark, Roeck Brent, Yang Zane, Raymond Victoria M, Lanman Richard B, Frampton Garrett M, Miller Vincent A, Schrock Alexa B, Albacker Lee A, Wong Kwok-Kin, Cross Jason B, Heymach John V
出版信息
Cancer Cell. 2020 Mar 16;37(3):420. doi: 10.1016/j.ccell.2020.03.003.
Abstract
摘要
相似文献
1
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.泛癌图谱及ERBB2突变分析确定波齐替尼为具有临床活性的抑制剂及T-DM1活性增强剂。
Cancer Cell. 2020 Mar 16;37(3):420. doi: 10.1016/j.ccell.2020.03.003.
2
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.一项针对泛HER抑制剂波齐替尼的II期试验，受试对象为接受过至少两种先前HER2靶向治疗方案的HER2阳性转移性乳腺癌患者：NOV120101-203试验结果
Int J Cancer. 2018 Dec 15;143(12):3240-3247. doi: 10.1002/ijc.31651. Epub 2018 Nov 7.
3
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.新型 HER2 抑制剂波齐替尼治疗肺癌 HER2 外显子 20 突变的活性及其获得性耐药机制的体外研究。
Lung Cancer. 2018 Dec;126:72-79. doi: 10.1016/j.lungcan.2018.10.019. Epub 2018 Oct 17.
4
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.分子改变与泛 HER 抑制剂波齐替尼在人表皮生长因子受体 2（HER2）阳性乳腺癌中的疗效：来自波齐替尼治疗难治性 HER2 阳性乳腺癌患者的 II 期临床试验的联合探索性生物标志物分析。
Int J Cancer. 2019 Sep 15;145(6):1669-1678. doi: 10.1002/ijc.32188. Epub 2019 Feb 27.
5
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.Tucatinib 联合 ado-trastuzumab emtansine 治疗晚期 ERBB2/HER2 阳性转移性乳腺癌：一项 1b 期临床试验。
JAMA Oncol. 2018 Sep 1;4(9):1214-1220. doi: 10.1001/jamaoncol.2018.1812.
6
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.一种对具有ERBB配体过表达的耐药HER2+乳腺癌具有高活性的ERBB1-3中和抗体混合物。
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.
7
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.HER2阳性转移性乳腺癌患者的治疗格局：来自PRAEGNANT真实世界乳腺癌登记处的数据。
Cancers (Basel). 2018 Dec 21;11(1):10. doi: 10.3390/cancers11010010.
8
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ()-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.波齐替尼在对表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂产生耐药的EGFR突变型肺腺癌患者中的II期研究。
Cancer Res Treat. 2017 Jan;49(1):10-19. doi: 10.4143/crt.2016.058. Epub 2016 May 3.
9
The Design, Synthesis and Preliminary Pharmacokinetic Evaluation of d3-Poziotinib Hydrochloride.d3-波齐替尼盐酸盐的设计、合成及初步药代动力学评价。
Biol Pharm Bull. 2019;42(6):873-876. doi: 10.1248/bpb.b19-00153.
10
Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.使用抗体细胞毒性药物偶联物T-DM1靶向HER2在HER2过表达的膀胱癌中有效。
J Urol. 2015 Oct;194(4):1120-31. doi: 10.1016/j.juro.2015.05.087. Epub 2015 Jun 3.
引用本文的文献
1
If it's a target, it's a pan-cancer target: Tissue is not the issue.如果是靶点，那就是泛癌靶点：组织不是问题。
Cancer Treat Rev. 2024 Apr;125:102721. doi: 10.1016/j.ctrv.2024.102721. Epub 2024 Mar 21.
2
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.RAS/RAF 突变与 ERBB2 拷贝数调节结直肠癌中 HER2 的异质性及对 HER2 靶向治疗的反应性
Clin Cancer Res. 2024 Apr 15;30(8):1669-1684. doi: 10.1158/1078-0432.CCR-23-2581.
3
Novel HER-2 Targeted Therapies in Breast Cancer.乳腺癌中的新型HER-2靶向疗法。
Cancers (Basel). 2023 Dec 23;16(1):87. doi: 10.3390/cancers16010087.
4
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy.解锁乳腺癌治疗新途径：激酶抑制剂与免疫疗法的协同作用
Cancers (Basel). 2023 Nov 21;15(23):5499. doi: 10.3390/cancers15235499.
5
Emerging Targeted Therapies for HER2-Positive Breast Cancer.HER2阳性乳腺癌的新兴靶向治疗方法
Cancers (Basel). 2023 Mar 26;15(7):1987. doi: 10.3390/cancers15071987.
6
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers.埃斯硒啉氧化物及其衍生物是一种新型的变构人表皮生长因子受体 2（HER2）抑制剂，用于治疗 HER2 阳性癌症。
Mol Oncol. 2023 Oct;17(10):1981-1999. doi: 10.1002/1878-0261.13419. Epub 2023 Mar 27.
7
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.吡咯替尼治疗 HER2 突变型晚期肺腺癌的有效性和安全性：一项多中心、单臂、Ⅱ期临床试验。
BMC Med. 2022 Feb 1;20(1):42. doi: 10.1186/s12916-022-02245-z.
8
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.表皮生长因子受体（EGFR）抑制增强了 HER3 抗体药物偶联物 HER3-DXd 的细胞摄取和抗肿瘤活性。
Cancer Res. 2022 Jan 1;82(1):130-141. doi: 10.1158/0008-5472.CAN-21-2426. Epub 2021 Sep 21.
9
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.非小细胞肺癌中的新型新兴分子靶点。
Int J Mol Sci. 2021 Mar 5;22(5):2625. doi: 10.3390/ijms22052625.
Zotero 插件